• J-Y Hwang, J-H Kim, A-Y Oh, S-H Do, Y-T Jeon, and S-H Han.
• Department of Anaesthesiology and Pain Medicine, Bundang Hospital, Seoul National University, Bundang-gu, Gyeonggi-do, Korea.
• J. Int. Med. Res. 2008 Jan 1;36(1):17-22.

AbstractEtomidate is a popular anaesthetic induction agent, but it frequently causes myoclonic movements. Although both benzodiazepines and opioids reduce myoclonus, there has been no comparative study between these agents. Thus, we conducted a prospective, randomized study to compare midazolam and remifentanil as pre-treatment agents for reducing etomidate-induced myoclonus in 90 adults undergoing surgery. Patients were pre-treated before the etomidate injection, either with saline (Group C), midazolam 0.5 mg/kg (Group M) or remifentanil 1 microg/kg (Group R). Both Groups M and R showed a significantly lower incidence of myoclonus compared with Group C (17%, 17% and 77%, respectively). The incidence of myoclonus was not significantly different between Groups M and R, but 10% (n = 10) of the patients in Group R experienced remifentanil-related side-effects. We conclude that midazolam is probably a better choice than remifentanil for reducing etomidate-induced myoclonus during anaesthesia induction.

19 keywords...

hide…